Abstract
Transforming growth factor-beta (TGF-β) is a multifunctional growth factor with a wide range of potential effects on growth, differentiation, extracellular matrix accumulation and the immune system. It has been implicated in many cardiovascular disorders. TGF-β actions are mediated via a complex between its type I and type II receptors resulting in the phosphorylation of receptor-specific Smads followed by their passage to the nucleus where they influence many transcriptional responses. TGF-β has important roles in the development of the neointima and constrictive remodeling associated with angioplasty. In atherosclerosis its actions are yet to be fully elucidated but its ability to control the immune system has profound effects on lesion development, particularly by influencing the types of lesions that develop. TGF-β can also induce arteriogenesis and markedly influences angiogenic processes, possessing both pro- and anti-angiogenic effects. It is also a major contributor to the development of various cardiovascular fibrotic disorders including those in the vasculature, heart and kidney. Targeting TGF-β prevents neointima formation and the constrictive remodeling associated with angioplasty and also prevents the development of many fibrotic disorders. This review summarizes TGF-β signaling pathways, the mechanisms by which TGF-β contributes to many of these cardiovascular diseases and examines the therapeutic potential of targeting TGF-β actions in preventing these disorders.
Keywords: transcription, dna binding proteins, transforming growth factor, antifibrotic effects
Current Vascular Pharmacology
Title: Transforming Growth Factor-β, Cell Signaling and Cardiovascular Disorders
Volume: 3 Issue: 1
Author(s): Alex Agrotis, Natalia Kalinina and Alex Bobik
Affiliation:
Keywords: transcription, dna binding proteins, transforming growth factor, antifibrotic effects
Abstract: Transforming growth factor-beta (TGF-β) is a multifunctional growth factor with a wide range of potential effects on growth, differentiation, extracellular matrix accumulation and the immune system. It has been implicated in many cardiovascular disorders. TGF-β actions are mediated via a complex between its type I and type II receptors resulting in the phosphorylation of receptor-specific Smads followed by their passage to the nucleus where they influence many transcriptional responses. TGF-β has important roles in the development of the neointima and constrictive remodeling associated with angioplasty. In atherosclerosis its actions are yet to be fully elucidated but its ability to control the immune system has profound effects on lesion development, particularly by influencing the types of lesions that develop. TGF-β can also induce arteriogenesis and markedly influences angiogenic processes, possessing both pro- and anti-angiogenic effects. It is also a major contributor to the development of various cardiovascular fibrotic disorders including those in the vasculature, heart and kidney. Targeting TGF-β prevents neointima formation and the constrictive remodeling associated with angioplasty and also prevents the development of many fibrotic disorders. This review summarizes TGF-β signaling pathways, the mechanisms by which TGF-β contributes to many of these cardiovascular diseases and examines the therapeutic potential of targeting TGF-β actions in preventing these disorders.
Export Options
About this article
Cite this article as:
Agrotis Alex, Kalinina Natalia and Bobik Alex, Transforming Growth Factor-β, Cell Signaling and Cardiovascular Disorders, Current Vascular Pharmacology 2005; 3 (1) . https://dx.doi.org/10.2174/1570161052773951
DOI https://dx.doi.org/10.2174/1570161052773951 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Nano-biotechnology and its Innovative Perspective in Diabetes Management
Mini-Reviews in Medicinal Chemistry Melatonin and Respiratory Diseases: A Review
Current Topics in Medicinal Chemistry Pupil Response Biomarkers Distinguish Amyloid Precursor Protein Mutation Carriers from Non-Carriers
Current Alzheimer Research Biologic Therapy in Psoriasis: Safety Profile
Current Drug Safety Insulin Treatment and Weight Gain in Type 2 Diabetes: Is Our Knowledge Complete?
Current Nutrition & Food Science Anti-apoptotic Serpins as Therapeutics in Cardiovascular Diseases
Cardiovascular & Hematological Disorders-Drug Targets Design, Synthesis and Preliminary Evaluation of Novel Imperatorin Derivatives as Vasorelaxant Agents
Medicinal Chemistry Re-Wiring the Circuit: Mitochondria as a Pharmacological Target in Liver Disease
Current Medicinal Chemistry The Pursuit of Differentiated Ligands for the Glucocorticoid Receptor
Current Topics in Medicinal Chemistry Expressions of eNOS3 and Ve-Cadherin in Microvascular Endothelium at 7-Day of Reperfused Acute Myocardial Infarction
Cardiovascular & Hematological Disorders-Drug Targets Effects of Drugs, Phytoestrogens, Nutrients and Probiotics on Endothelial Dysfunction in the Estrogen-Deficient State
Current Pharmaceutical Design The Etiology of Hypertension in the Metabolic Syndrome Part Two: The Gene-Environment Interaction
Current Vascular Pharmacology Promoters and Control Elements: Designing Expression Cassettes for Gene Therapy
Current Gene Therapy Meeting Report: The Fourth Annual PepTalk Meeting: The Human Proteome
Current Proteomics Nongenomic Actions of Retinoids: Role of Nur77 and RXR in the Regulation of Apoptosis and Inflammation
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry The Neuropathology of Vascular Disease in the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS)
Current Alzheimer Research Prevalence of HTN in Iran: Meta-analysis of Published Studies in 2004-2018
Current Hypertension Reviews Diminished Renal Function and the Incidence of Heart Failure
Current Cardiology Reviews Identification of Neuronal Nitric Oxide Synthase (nNOS) in Human Penis: a Potential Role of Reduced Neuronally-derived Nitric Oxide in Erectile Dysfunction
Current Pharmaceutical Biotechnology Editorial (Thematic Issues: Managing the Cardiovascular Risk Associated with the Metabolic Syndrome)
Current Pharmaceutical Design